Oxyntomodulin Differentially Affects Glucagon-Like Peptide-1 Receptor β-Arrestin Recruitment and Signaling through Gα
- 7TM Pharma A/S, Horsholm, Denmark (R.J., T.W.S., C.E.E.); Institute of Anatomy, Histology, and Embryology, Veterinary Faculty, University of Ljubljana, Ljubljana, Slovenia (V.K., M.V.); Laboratory for Molecular Pharmacology, Panum Institute, University of Copenhagen, Blegdamsvej, Denmark (T.W.S.)
- Address correspondence to:
Dr. Christian E. Elling, 7TM Pharma A/S, 2970 Horsholm, Denmark. E-mail: cee{at}7tm.com
Abstract
The glucagon-like peptide (GLP)-1 receptor is a promising target for the treatment of type 2 diabetes and obesity, and there is great interest in characterizing the pharmacology of the GLP-1 receptor and its ligands. In the present report, we have applied bioluminescence resonance energy transfer2 assays to measure agonist-induced recruitment of βarrestins and G-protein-coupled receptor kinase (GRK) 2 to the GLP-1 receptor in addition to traditional measurements of second messenger generation. The peptide hormone oxyntomodulin is described in the literature as a full agonist on the glucagon and GLP-1 receptors. Surprisingly, despite being full agonists in GLP-1 receptor-mediated cAMP accumulation, oxyntomodulin and glucagon were observed to be partial agonists in recruiting βarrestins and GRK2 to the GLP-1 receptor. We suggest that oxyntomodulin and glucagon are biased ligands on the GLP-1 receptor.
Footnotes
-
Article, publication date, and citation information can be found at http://jpet.aspetjournals.org.
-
doi:10.1124/jpet.107.120006.
-
ABBREVIATIONS: 7TM, seven transmembrane; GLP, glucagon-like peptide; GRK, G-protein-coupled receptor kinase; GFP, green fluorescent protein; βarr, β-arrestin; RLuc, Renilla luciferase; BRET, bioluminescence resonance energy transfer; wt, wild type; PTH, parathyroid hormone; MAP, mitogen-activated protein.
-
↵
The online version of this article (available at http://jpet.aspetjournals.org) contains supplemental material.
-
- Received January 16, 2007.
- Accepted March 28, 2007.
- The American Society for Pharmacology and Experimental Therapeutics



